Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 323

1.

Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis.

Distler O, Pap T, Kowal-Bielecka O, Meyringer R, Guiducci S, Landthaler M, Schölmerich J, Michel BA, Gay RE, Matucci-Cerinic M, Gay S, Müller-Ladner U.

Arthritis Rheum. 2001 Nov;44(11):2665-78.

PMID:
11710722
2.

Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression.

Galindo M, Santiago B, Rivero M, Rullas J, Alcami J, Pablos JL.

Arthritis Rheum. 2001 Jun;44(6):1382-6.

3.

Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts.

Brembilla NC, Montanari E, Truchetet ME, Raschi E, Meroni P, Chizzolini C.

Arthritis Res Ther. 2013 Oct 10;15(5):R151. doi: 10.1186/ar4334.

4.

Expression of monocyte chemoattractant protein-1 in the lesional skin of systemic sclerosis.

Yamamoto T, Eckes B, Hartmann K, Krieg T.

J Dermatol Sci. 2001 Jun;26(2):133-9.

PMID:
11378330
5.

Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse.

Ong VH, Evans LA, Shiwen X, Fisher IB, Rajkumar V, Abraham DJ, Black CM, Denton CP.

Arthritis Rheum. 2003 Jul;48(7):1979-91.

6.

High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts.

Yamamoto T, Eckes B, Krieg T.

Eur J Immunol. 2001 Oct;31(10):2936-41.

PMID:
11592069
7.

Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells.

Distler JH, Jüngel A, Caretto D, Schulze-Horsel U, Kowal-Bielecka O, Gay RE, Michel BA, Müller-Ladner U, Kalden JR, Gay S, Distler O.

Arthritis Rheum. 2006 Jan;54(1):214-25.

9.

Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors.

Kawaguchi Y, Takagi K, Hara M, Fukasawa C, Sugiura T, Nishimagi E, Harigai M, Kamatani N.

Arthritis Rheum. 2004 Jan;50(1):216-26.

10.

The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis.

Reich N, Maurer B, Akhmetshina A, Venalis P, Dees C, Zerr P, Palumbo K, Zwerina J, Nevskaya T, Gay S, Distler O, Schett G, Distler JH.

Arthritis Rheum. 2010 Jan;62(1):280-90. doi: 10.1002/art.25056.

11.

Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis.

Distler JH, Akhmetshina A, Schett G, Distler O.

Rheumatology (Oxford). 2009 Feb;48(2):98-103. doi: 10.1093/rheumatology/ken401. Epub 2008 Nov 4. Review.

13.

MicroRNA-29, a key regulator of collagen expression in systemic sclerosis.

Maurer B, Stanczyk J, Jüngel A, Akhmetshina A, Trenkmann M, Brock M, Kowal-Bielecka O, Gay RE, Michel BA, Distler JH, Gay S, Distler O.

Arthritis Rheum. 2010 Jun;62(6):1733-43. doi: 10.1002/art.27443.

14.

Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblasts.

Tsou PS, Talia NN, Pinney AJ, Kendzicky A, Piera-Velazquez S, Jimenez SA, Seibold JR, Phillips K, Koch AE.

Arthritis Rheum. 2012 Jun;64(6):1978-89. doi: 10.1002/art.34336. Epub 2011 Dec 12.

15.

Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis.

Distler JH, Jüngel A, Kowal-Bielecka O, Michel BA, Gay RE, Sprott H, Matucci-Cerinic M, Chilla M, Reich K, Kalden JR, Müller-Ladner U, Lorenz HM, Gay S, Distler O.

Arthritis Rheum. 2005 Mar;52(3):856-64.

16.

Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1.

Akamata K, Asano Y, Aozasa N, Noda S, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Sato S.

Arthritis Res Ther. 2014 Apr 3;16(2):R86. doi: 10.1186/ar4529.

17.

Expression of hepatocyte growth factor and its receptor (c-met) in skin fibroblasts from patients with systemic sclerosis.

Kawaguchi Y, Harigai M, Hara M, Fukasawa C, Takagi K, Tanaka M, Tanaka E, Nishimagi E, Kamatani N.

J Rheumatol. 2002 Sep;29(9):1877-83.

PMID:
12233882
18.
20.

Supernatants from culture of type I collagen-stimulated PBMC from patients with cutaneous systemic sclerosis versus localized scleroderma demonstrate suppression of MMP-1 by fibroblasts.

Brown M, Postlethwaite AE, Myers LK, Hasty KA.

Clin Rheumatol. 2012 Jun;31(6):973-81. doi: 10.1007/s10067-012-1962-z. Epub 2012 Feb 25.

Supplemental Content

Support Center